Atopic Dermatitis Severity Tied to IgG Response to S. Aureus

This article originally appeared here.
Share this content:
Atopic Dermatitis Severity Tied to IgG Response to <i>S. Aureus</i>
Atopic Dermatitis Severity Tied to IgG Response to S. Aureus

TUESDAY, Dec. 12, 2017 (HealthDay News) -- Atopic dermatitis (AD) disease severity is associated with immunoglobulin G (IgG) responses against Staphylococcus aureus antigens, according to a study published online Nov. 30 in the British Journal of Dermatology.

Joan E.E. Totté, M.D., from the Erasmus MC University Medical Centre in the Netherlands, and colleagues profiled IgG antibodies against 55 S. aureus antigens in sera of 207 children with mild-to-severe AD from two separate cohorts.

The researchers found that in the first cohort, 16 antigens were associated with Self Administrated-Eczema Area and Severity Index (SA-EASI) and 12 antigens were associated with thymus and activation-regulated chemokine (TARC) in serum (10 overlapping antigens; P values from 0.001 to 0.044). In the second cohort, IgG levels against only four S. aureus antigens were associated with SA-EASI and one with TARC, although there was no overlap.

"In young children, severity of AD is associated with an IgG response directed against S. aureus antigens with mainly immune-modulatory functions," the authors write. "These findings encourage further evaluation of the role of S. aureus in AD pathogenesis."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »